Ultrasound-guided intra-articular corticosteroid injection for symptomatic knee osteoarthritis — suprapatellar & lateral midpatellar approaches
Knee osteoarthritis (OA) affects an estimated 365 million people worldwide and is a leading cause of disability in adults over 50. When conservative measures — weight loss, physiotherapy, oral/topical NSAIDs, and activity modification — fail to control pain, ultrasound-guided intra-articular corticosteroid injection (IACI) is a widely used second-line option, particularly in patients with a clinically evident effusion or synovitis.
The decision to inject begins with a structured evaluation:
• History: mechanical pain pattern, morning stiffness <30 minutes, activity-related pain, prior injection response, allergy history (local anesthetic, corticosteroid vehicle) • Exam: joint line tenderness, bony crepitus, effusion (patellar tap, bulge sign), range of motion, varus/valgus alignment, quadriceps strength • Imaging: weight-bearing AP/lateral/skyline radiographs graded by the Kellgren-Lawrence (K-L) system (0–4); MRI reserved for atypical presentations or suspected internal derangement • Point-of-care ultrasound: quantifies suprapatellar recess fluid depth (>4 mm anechoic stripe = effusion), synovial hypertrophy (hypoechoic/Doppler-positive pannus), and Baker cyst
American College of Rheumatology (ACR) 2019 and OARSI guidelines conditionally recommend intra-articular corticosteroid for knee OA with an effusion or synovitis, particularly for short-term flare management, while cautioning against high-frequency repeated dosing.
A palpable or sonographically confirmed effusion increases the pretest probability that a corticosteroid injection — rather than viscosupplementation or an oral agent — will provide meaningful short-term relief, because corticosteroids act directly on synovial inflammation.
Absolute contraindications: overlying cellulitis or skin infection at the injection site, suspected septic arthritis, bacteremia, and known hypersensitivity to the corticosteroid or anesthetic vehicle.
Relative contraindications: uncontrolled diabetes mellitus (corticosteroid can transiently raise blood glucose 24–48h), anticoagulation (small-gauge needle injections are generally safe per 2018 EULAR points to consider, but INR should be checked if supratherapeutic), prosthetic joint (should be performed by/with experienced proceduralists to minimize infection risk), and more than 3 injections in the preceding 12 months in the same joint.
Patients with advanced K-L grade IV (bone-on-bone) disease and minimal effusion have a lower likelihood of clinically important benefit and should be counseled about surgical referral (total knee arthroplasty) alongside injection.
Correct probe selection, patient positioning, and systematic sonoanatomic survey are the foundation of an accurate, low-risk injection. The suprapatellar recess is the largest and most consistently distensible synovial reflection of the knee, making it the preferred target for both diagnostic aspiration and therapeutic injection.
A high-frequency (6–15 MHz) linear-array transducer provides the spatial resolution (as fine as 0.1–0.3 mm axially) required to distinguish the thin hyperechoic synovial capsule from anechoic fluid and hypoechoic synovium. Lower frequencies (6–8 MHz) trade resolution for penetration in higher-BMI patients; higher frequencies (12–15 MHz) are preferred for thin patients and superficial structures such as the midpatellar recess.
Longitudinal (sagittal) scan over the anterior thigh identifies, from superficial to deep: subcutaneous fat, quadriceps tendon (fibrillar hyperechoic band), suprapatellar fat pad, suprapatellar recess (potential space, distends with effusion), and the anterior femoral cortex (bright hyperechoic line with posterior acoustic shadowing).
Transverse scan at the level of the mid-patella (lateral midpatellar view) shows the patella medially, the lateral femoral condyle, and the lateral joint recess/synovial reflection — the classic entry point for the lateral midpatellar approach.
Semi-quantitative grading (OMERACT ultrasound definitions) is used to characterize the suprapatellar recess:
• Grade 0: no anechoic fluid • Grade 1: minimal anechoic distension • Grade 2: moderate distension with mild capsular bulging • Grade 3: marked distension with capsular ballooning
Synovial hypertrophy appears as non-displaceable, hypoechoic, poorly compressible tissue that may show Power Doppler signal indicating active hyperemic synovitis — a further indication for corticosteroid over viscosupplementation, since corticosteroids exert a direct anti-inflammatory effect on Doppler-positive synovium.
Two validated ultrasound-guided approaches dominate clinical practice: the lateral midpatellar approach (short-axis probe, needle in-plane, horizontal trajectory into the lateral recess) and the suprapatellar approach (long-axis probe over the quadriceps tendon, needle in-plane, trajectory parallel to the femoral shaft into the recess). Both achieve procedural accuracy exceeding 95% in cadaveric and clinical validation studies.
1. Sterile prep of skin and probe cover (sterile gel or sheath) per ESSR/ACR guidance point-of-care ultrasound standards. 2. Identify target recess in the plane of choice; mark the needle entry point roughly 1 cm from the probe's short edge to allow a shallow 20–30° trajectory. 3. Raise a subcutaneous lidocaine skin wheal with a 25–27G needle if local anesthesia is desired before the larger injection needle. 4. Advance the 21–22G needle in-plane with the ultrasound beam, keeping the entire shaft and the bevel tip continuously visualized as a bright, reverberating hyperechoic line with posterior comet-tail/reverberation artifact. 5. Confirm intra-articular position by observing the needle tip enter the anechoic fluid stripe, by easy aspiration of synovial fluid, or — if dry-tapping — by watching anechoic anesthetic bolus distend the recess (hydrodissection sign) on injection of a 1 mL test dose.
The lateral midpatellar approach uses a short-axis (transverse) probe position with the needle entering laterally and horizontally, well suited to smaller effusions because the joint space is wider mediolaterally at this level. The suprapatellar approach uses a long-axis probe position parallel to the quadriceps tendon, favored when a large, easily distended recess is present.
In-plane needle visualization allows the entire needle shaft and tip to be tracked continuously, essentially eliminating the risk of inadvertent penetration of the femoral cortex, patellar cartilage, or neurovascular structures — a key safety advantage over blind, landmark-based injection.
Common technical errors include losing the needle tip out of the ultrasound beam plane (mistaking shaft reverberation artifact for the tip), advancing too steeply and striking articular cartilage, and failing to angle the transducer to align with anisotropic tendon fibers (which can be mistaken for pathology). Continuous minor probe tilting ("heel-toe" maneuvers) keeps the beam perpendicular to the needle shaft, maximizing its echogenicity throughout the approach.
Once intra-articular position is confirmed, any effusion is aspirated before injecting the corticosteroid-anesthetic mixture. Real-time visualization of the injectate spreading and swirling within the recess — rather than pooling in soft tissue — is the definitive sonographic confirmation of a successful intra-articular injection.
A large effusion is aspirated to dryness using a 18–20G needle or the same needle with a three-way stopcock, both to relieve mechanical pressure/pain and to obtain fluid for synovial analysis (cell count, Gram stain/culture, crystal examination) when infection or crystal arthropathy is a concern.
Standard injectate: triamcinolone acetonide 40 mg/mL (1 mL) or methylprednisolone acetate 40–80 mg, combined with 3–5 mL of 1% lidocaine or 0.25% bupivacaine both for immediate diagnostic/analgesic effect and to dilute the steroid suspension for even intra-articular distribution. Total volume 4–6 mL is typical for the knee, the body's largest synovial joint.
Real-time dynamic scanning during injection should show:
• Anechoic-to-mixed-echogenicity fluid actively distending the recess as it is injected ("ballooning sign") • Swirling turbulent flow of the injectate mixing with residual synovial fluid • Absence of localized soft-tissue bulging outside the capsule (which would indicate extra-articular/periarticular misplacement) • Low injection resistance — high resistance suggests the needle tip is within tendon, capsule, or cartilage rather than the joint space
Studies directly comparing palpation-guided versus ultrasound-guided knee injection (Sibbitt et al., J Rheumatol 2009; Chest/Rheum literature) consistently show ultrasound guidance improves accuracy from roughly 70–80% to 95–99%, and improves clinical outcomes (pain reduction, cost-effectiveness) versus blind injection.
Ultrasound-guided intra-articular corticosteroid injection is safe and modestly effective for symptomatic knee OA flares, but the evidence base supports realistic expectations: benefit is typically short-lived, and emerging data on cartilage effects with frequent repeated dosing have tempered enthusiasm for unrestricted use.
Cochrane systematic reviews and multiple randomized trials show intra-articular corticosteroid produces statistically significant but often only moderate, short-term (2–6 week) pain reduction compared with placebo, with effect sizes diminishing by 12–24 weeks. The 2019 ACR/Arthritis Foundation guideline gives a conditional recommendation for use in symptomatic knee OA; OARSI (2019) and ESSR similarly support use for flares, particularly with effusion/synovitis, but not as a first-line or standalone long-term disease-modifying strategy.
McAlindon et al. (JAMA 2017) randomized 140 patients to intra-articular triamcinolone versus saline every 12 weeks for 2 years and found no difference in pain scores but significantly greater cartilage volume loss on MRI in the triamcinolone group (mean difference in cartilage thickness loss −0.21 mm), prompting more conservative dosing-frequency recommendations.
The cumulative evidence supports intra-articular corticosteroid as a tool for short-term flare control — best reserved for patients with a clinically significant effusion or synovitis — rather than a repeated, indefinite maintenance therapy, given cartilage-volume signals from long-term repeated-dosing trials.
• Post-injection flare (steroid crystal synovitis): 2–5% of patients, self-limited within 24–48 hours, managed with ice and analgesia • Facial flushing: up to 10%, more common with triamcinolone, self-limited • Skin/subcutaneous atrophy and hypopigmentation at injection site: rare with intra-articular (vs. more common with periarticular/soft-tissue) injection • Transient hyperglycemia in diabetic patients: 24–48 hours, dose-dependent • Septic arthritis: rare (estimated 1 in 10,000–50,000 injections) with proper sterile technique, but a feared complication requiring prompt recognition (progressive pain, warmth, effusion, fever) and arthrocentesis • Tendon or cartilage injury: minimized by real-time ultrasound visualization of the needle tip throughout the procedure
Patients are counseled to seek urgent evaluation for increasing pain, redness, warmth, or fever after injection, as these findings should prompt evaluation for septic arthritis regardless of how rare it is.